ASCO 2024 Poster for Trial #19-09

Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.

Wednesday, June 19, 2024

Dr. Minal Barve

Read the Story Here

Click above link to view abstract, login required to view video presentation.

ASCO 2024 Poster for Trial 19-09

ASCO 2024 Poster for Trial 19-09

Click to view ASCO 2024 Poster for Trial 19-09 Full size

Related Abstracts

Discover more abstracts for our trials.

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider

Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

Sep 24, 2024

Dr. Reva Schneider

First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients

Sep 24, 2024

Dr. Douglas Orr
See All Posts